Novel drug combination for nocturia
Took the program from protocol development, manufacturing guidance and pre-IND meeting through IND activation and a Phase II trial, in exchange for equity.
Partnerships
We invest in the programs we believe in.
Great science often stalls for lack of capital, not merit. For promising early-stage drugs, biologics, devices and diagnostics, Axella can take part of its fee in equity, royalties or milestones and, case by case, co-fund clinical development. Your success becomes ours.
Partnership models
Flexible structures that share the risk.
Every partnership is built around the program. Most combine a reduced cash fee with one or more of the structures below.
Model 01
Equity
Services for equity
Part of our fee for regulatory, operations and site services is taken as equity in your company, so we're invested in the outcome, not just the invoice.
Model 02
Royalty
Royalties or milestones
Deferred or reduced fees in exchange for a royalty on future revenue or payments tied to clinical and regulatory milestones.
Model 03 · Case by case
Co-fund
Co-funded development
For select programs, Axella may co-fund a portion of clinical development costs alongside the sponsor, sharing both the investment and the upside.
How it works
From first conversation to first patient.
A straightforward, confidential process. You'll speak with senior leadership from the start, not a business-development queue.
01
Submit your programShare a short overview. We're happy to sign an NDA before you share anything confidential.
02
Scientific and regulatory reviewOur team assesses the science, the regulatory path, the development plan and the market opportunity.
03
Structure the partnershipWe propose a mix of cash fees with equity, royalties, milestones and, where it fits, co-funding.
04
Execute togetherThe same team runs regulatory strategy, sites and operations, from the FDA to the clinic.
What we look for
Selective by design.
We take on a limited number of partnerships so each gets our full attention. The strongest candidates share a few traits.
Compelling scienceA clear mechanism and early data that support moving into the clinic.
A defined regulatory pathA realistic route to IND, IDE or approval that we can help accelerate.
Real unmet needA meaningful patient population and a credible commercial opportunity.
Protectable positionIntellectual property or know-how that creates lasting value.
A committed teamFounders and scientists ready to work alongside us.
Track record
We've done this before.
IVD test for bladder cancer detection
FDA submission strategy and clinical studies for a novel in-vitro diagnostic, under a royalty partnership.
Questions
Partnership FAQ
Do we have to offer equity to work with Axella?
No. Most of our clients work with us on a standard fee-for-service basis. Partnership is an option for programs where shared risk makes sense for both sides.
Does a partnership replace raising capital?
No. It complements your financing. By reducing cash spent on development services, a partnership can extend your runway and help you reach value-building milestones sooner.
When does Axella co-fund development?
Co-funding is considered case by case, typically for programs with strong early data and a clear regulatory path where our contribution can meaningfully change the trajectory.
Is our information kept confidential?
Yes. We're glad to sign a mutual NDA before you share any confidential information, and your submission is reviewed only by our leadership team.
What stage of programs do you consider?
Most often programs approaching or entering the clinic, from pre-IND through Phase II, across drugs, biologics, devices and diagnostics.
Partnership terms, including any equity, royalty, milestone or co-funding arrangement, are evaluated case by case and are subject to due diligence and definitive written agreements. Nothing on this page is an offer to buy or sell securities or a solicitation of investment.
Have a program worth partnering on?
Send us a short overview. Our leadership team will review it and respond within a few business days.